Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Vaxcyte's VAX-24?
VAX-24 is a conjugate vaccine commercialized by Vaxcyte, with a leading Phase II program in Streptococcal Pneumonia. According to Globaldata,...
Data Insights
Risk adjusted net present value: What is the current valuation of Vaxcyte's VAX-24?
VAX-24 is a conjugate vaccine commercialized by Vaxcyte, with a leading Phase II program in Streptococcal Pneumonia. According to Globaldata,...